SCHEMBL1378422

SCHEMBL1378422

COCCCNC(=O)c1cncc(-c2cc(-c3cc(OC)c(OC)c(OC)c3)n(S(=O)(=O)c3ccc(C)cc3)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 1/20 0.40
ALOX15 P16050 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 1/20 0.39
LMNA P02545 1/20 0.38
USP2 O75604 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
RAD52 P43351 1/20 0.37
FYN P06241 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3369860 0.86 L3MBTL1 (0.40) MAPTHTTKMT2AMEN1GAA
SCHEMBL1376787 0.86 CD274 (0.44) KDM4EALDH1A1KMT2ANPC1RAB9A
SCHEMBL1379796 0.84 MAPK1 (0.38) ALDH1A1KMT2A
SCHEMBL1376476 0.84 MAP3K11 (0.42) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL1379148 0.80 KDM4E (0.37) KDM4EALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL1379771 0.80 MAPT (0.37) MAPTKDM4EALDH1A1KMT2AMEN1
SCHEMBL1378956 0.77 CYP11B1 (0.47) MAPTALDH1A1L3MBTL1LMNAFYN
SCHEMBL1379606 0.74 MAP3K11 (0.48) ALDH1A1KMT2AL3MBTL1FYN
SCHEMBL3370766 0.73 CD274 (0.42) KDM4EALDH1A1GAANPC1RAB9A
SCHEMBL1376420 0.71 CA2 (0.61) MAPTKDM4EALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4716996-B2 2011-07-06 JP claimed
EP-1628957-B1 SULFOPYRROLES TAKEDA PHARMACEUTICAL (JP) 2010-09-29 EP claimed
US-20070060570-A1 Sulfopyrroles TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-15 US claimed
EP-1628957-A1 SULFOPYRROLES Takeda Pharmaceutical Company Limited (JP) 2006-03-01 EP claimed
WO-2004103968-A1 SULFOPYRROLES APONETICS AG (CH) 2004-12-02 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060570-A1 Sulfopyrroles TYK2, ARSA, SULT2A1 MAPT 4766/4885KDM4E 3031/4885ALDH1A1 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.